CERUS CORP
Business
Cerus Corp is a biomedical products company developing and commercializing the INTERCEPT Blood System, a proprietary technology designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers FDA-approved platelet and plasma systems for commercial use in multiple countries, an FDA-approved cryoprecipitation system for fibrinogen complex production, and a red blood cell system in clinical development. Cerus markets and sells its products through direct sales forces in the U.S. and Europe, through its wholly-owned European subsidiary, and via distributors in select international regions including the Commonwealth of Independent States, Middle East, and Latin America.
Summary from 10-K filed 2026-03-02
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 234 | 201 | 187 | 188 | 160 | |
| Research and development | 68 | 59 | 68 | 64 | 64 | |
| Selling, general and administrative | 81 | 76 | 76 | 83 | 81 | |
| Restructuring | — | 0 | 4 | — | — | |
| Total operating expenses | 149 | 135 | 147 | 147 | 145 | |
| Loss from operations | −9 | −14 | −30 | −34 | −49 | |
| Foreign exchange (loss) gain | −1 | 370,000 | −648,000 | −690,000 | −572,000 | |
| Interest expense | −8 | −9 | −8 | −6 | — | |
| Other income, net | 3 | 2 | 2 | −2 | 374,000 | |
| Total non-operating expense, net | −7 | −7 | −7 | −8 | −5 | |
| Loss before income taxes | −15 | −21 | −37 | −42 | −54 | |
| Provision for income taxes | 354,000 | 205,000 | 325,000 | 488,000 | 319,000 | |
| Net loss | −16 | −21 | −38 | −43 | −54 | |
| Net loss attributable to noncontrolling interest | −10,000 | −43,000 | −158,000 | −46,000 | −2,000 | |
| Net loss attributable to Cerus Corporation | −16 | −21 | −37 | −43 | −54 | |
| Basic (per share) | −0.08 | −0.11 | −0.21 | −0.24 | −0.32 | |
| Diluted (per share) | −0.08 | −0.11 | −0.21 | −0.24 | −0.32 | |
| Basic (shares) | 191 | 185 | 180 | 177 | 171 | |
| Diluted (shares) | 191 | 185 | 180 | 177 | 171 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 20 | 20 | 12 | 36 | 49 | |
| Short-term investments | 63 | 60 | 54 | 67 | 81 | |
| Accounts receivable, net | 30 | 30 | 36 | 34 | 25 | |
| Current inventories | 56 | 38 | 40 | 29 | 27 | |
| Prepaid and other current assets | 5 | 4 | 3 | 5 | 6 | |
| Total current assets | 174 | 152 | 144 | 170 | 187 | |
| Property and equipment, net | 9 | 7 | 9 | 11 | 12 | |
| Operating lease right-of-use assets | 10 | 8 | 11 | 13 | 13 | |
| Goodwill | 1 | 1 | 1 | 1 | 1 | |
| Restricted cash | 639,000 | 1 | 2 | 2 | 2 | |
| Non-current inventories | 15 | 14 | 20 | 15 | — | |
| Other assets | 11 | 17 | 11 | 6 | 22 | |
| Total assets | 222 | 201 | 198 | 218 | 237 | |
| Accounts payable | 28 | 22 | 24 | 33 | 36 | |
| Accrued liabilities | 25 | 19 | 19 | 25 | 26 | |
| Debt current | 43 | 19 | 20 | 56 | 15 | |
| Operating lease liabilities current | 3 | 2 | 2 | 2 | 2 | |
| Deferred revenue | 1 | 1 | 2 | 589,000 | 673,000 | |
| Total current liabilities | 101 | 64 | 68 | 117 | 79 | |
| Debt non-current | 41 | 65 | 60 | 14 | 55 | |
| Operating lease liabilities non-current | 10 | 12 | 14 | 15 | 16 | |
| Other non-current liabilities | 5 | 4 | 3 | 3 | 2 | |
| Total liabilities | 157 | 144 | 144 | 150 | 152 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 5,000 shares authorized, issuable in series; zero shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — | — | — | — | |
| Common stock, $0.001 par value; 400,000 and 400,000 shares authorized; 192,142 and 185,766 shares issued and outstanding at December 31, 2025 and 2024, respectively | 192,000 | 186,000 | 181,000 | 177,000 | 174,000 | |
| Additional paid-in capital | 1,145 | 1,122 | 1,098 | 1,077 | 1,049 | |
| Accumulated other comprehensive loss | −156,000 | −400,000 | −1 | −3 | −149,000 | |
| Accumulated deficit | −1,081 | −1,066 | −1,045 | −1,007 | −964 | |
| Total Cerus Corporation stockholders' equity | 64 | 56 | 53 | 68 | 85 | |
| Noncontrolling interest | 741,000 | 751,000 | 794,000 | 952,000 | 998,000 | |
| Total liabilities and stockholders' equity | 222 | 201 | 198 | 218 | 237 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 1 | 2 | 3 | 3 | 3 | |
| Stock-based compensation | 23 | 23 | 20 | 24 | 24 | |
| Non-cash operating lease cost | 3 | 2 | 2 | 2 | 1 | |
| Net (gain) loss on sale of available-for-sale securities | −6,000 | 7,000 | 54,000 | 108,000 | −21,000 | |
| Unrealized gain on investments | −204,000 | −135,000 | −170,000 | −564,000 | −267,000 | |
| Loss on disposal of fixed assets | — | 3,000 | 65,000 | — | — | |
| Impairment charges for facilities consolidation | 0 | 0 | 2 | 0 | — | |
| Non-cash interest expense | 398,000 | 398,000 | 374,000 | 609,000 | 591,000 | |
| Foreign currency remeasurement loss (gain) | 290,000 | −388,000 | −685,000 | 2 | 511,000 | |
| Accounts receivable | −396,000 | 6 | −1 | −9 | −4 | |
| Inventories | −15 | 7 | −15 | −2 | −20 | |
| Prepaid and other assets | −2 | −3 | −994,000 | 1 | 3 | |
| Accounts payable | 6 | −1 | −7 | −5 | 12 | |
| Accrued liabilities and other non-current liabilities | 4 | −2 | −9 | −1 | 47,000 | |
| Deferred revenue | −124,000 | −603,000 | 1 | −84,000 | 96,000 | |
| Net cash provided by (used in) operating activities | 5 | 11 | −43 | −26 | −34 | |
| Capital expenditures | −4 | −3 | −5 | −2 | −910,000 | |
| Purchases of investments | −43 | −43 | −2 | −30 | −52 | |
| Proceeds from maturities and sale of investments | 40 | 38 | 16 | 40 | 66 | |
| Net cash (used in) provided by investing activities | −6 | −8 | 9 | 8 | 13 | |
| Net proceeds from equity incentives | 595,000 | 804,000 | 925,000 | 4 | 9 | |
| Net costs from public offerings | −35,000 | −137,000 | −175,000 | −104,000 | 3 | |
| Net (payments on) proceeds from revolving line of credit | −329,000 | −703,000 | 5 | 212,000 | — | |
| Proceeds from loans, net of issuance costs | — | 5 | 5 | — | 15 | |
| Net cash provided by financing activities | 231,000 | 5 | 11 | 4 | 34 | |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | 336,000 | −191,000 | −128,000 | −727,000 | −919,000 | |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | −761,000 | 8 | −24 | −14 | 12 | |
| Cash paid for interest | 9 | 9 | 9 | 5 | 4 | |
| Cash paid for income taxes | 301,000 | 356,000 | 322,000 | 270,000 | 278,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CERUS CORP's CIK number?
CERUS CORP's SEC CIK number is 0001020214 (1020214). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CERUS CORP's SEC filings?
All of CERUS CORP's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CERUS CORP last report earnings?
CERUS CORP (CERS) most recently filed an earnings 8-K with the SEC on Apr 30, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-197129). This is CERUS CORP's most recent earnings filing of record — not a forecast of its next earnings date.
What is CERUS CORP's most recent earnings 8-K?
CERUS CORP's latest earnings 8-K (Item 2.02) was filed Apr 30, 2026 under accession 0001193125-26-197129. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CERUS CORP's latest earnings 8-K →
Look up any company's CIK number →